Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors
IVERIC bio, Inc. announced the election of Pravin U. Dugel, MD, as a Board Member effective January 1, 2023. Dr. Dugel, instrumental in developing avacincaptad pegol (ACP), an investigational drug for geographic atrophy, aims to enhance the company's strategy ahead of potential FDA approval. The GATHER clinical trials showed promising results, meeting primary endpoints for ACP. With Doug's extensive experience, IVERIC bio positions itself strongly for future advancements in treating age-related macular degeneration.
- Dr. Pravin U. Dugel's election to the board adds experienced leadership.
- Dr. Dugel's role may strengthen strategic oversight as IVERIC prepares for ACP's potential approval.
- Successful results from the GATHER clinical trials enhance prospects for ACP.
- No negative aspects were identified in the press release.
“On behalf of the entire Board of Directors, we are excited to have Pravin join our board during this pivotal time as the Company prepares for a potential approval and commercial launch of ACP in geographic atrophy,” stated
“Pravin is an exceptional leader whose skills as an executive and extensive knowledge as a retinal specialist provide a valued perspective that will enhance the collective experience of our Board,” stated
“I look forward to adding to my responsibilities by serving as a board member of the Company and I am particularly honored to be among this group of talented and diverse board members,” stated Pravin U. Dugel, MD, President of
Pravin U. Dugel, MD
About Geographic Atrophy
Age-related macular degeneration (AMD) is the major cause of moderate and severe loss of central vision in aging adults, affecting both eyes in the majority of patients. The macula is a small area in the central portion of the retina responsible for central vision. As AMD progresses, the loss of retinal cells and the underlying blood vessels in the macula results in marked thinning and/or atrophy of retinal tissue. Geographic atrophy, the advanced stage of AMD, leads to further irreversible loss of vision in these patients. There are currently no
About Avacincaptad Pegol
Avacincaptad pegol (ACP) is an investigational drug that has not yet been evaluated by any regulatory body for safety and efficacy. ACP is not authorized for any indication in any country. ACP is a novel complement C5 protein inhibitor. Overactivity of the complement system and the C5 protein are suspected to play a critical role in the development and growth of scarring and vision loss associated with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). By targeting C5, ACP has the potential to decrease activity of the complement system that causes the degeneration of retinal cells and potentially slow the progression of GA.
About the GATHER Clinical Trials
ACP met its primary endpoint in the completed GATHER1 clinical trial and the ongoing GATHER2 clinical trial both of which are randomized, double-masked, sham-controlled, multicenter Phase 3 clinical trials. These clinical trials measured the efficacy and safety of monthly 2 mg intravitreal administration of ACP in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either ACP 2 mg or sham monthly. There were 286 participants enrolled in GATHER1 and 448 participants enrolled in GATHER2. The primary efficacy endpoints in both pivotal studies were based on GA area measured by fundus autofluorescence at three time points: Baseline, Month 6, and Month 12. The mean rate of growth (slope) in GA area from baseline to month 12 using observed data was
About Breakthrough Therapy Designation
Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). The FDA will review the full data submitted to support approval of drugs designated as breakthrough therapies to determine whether the drugs are safe and effective for their intended use before they are approved for marketing.
About
Forward-looking Statements
Any statements in this press release about the Company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this press release, the Company’s forward-looking statements include statements about its expectations regarding its development and regulatory strategy for ACP, the impact of FDA designations and the potential approvability and timelines for review of ACP, and the potential utility of ACP in treating geographic atrophy. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to expectations for regulatory matters, interpretation of clinical trial results by the scientific and medical community, developments from the Company’s competitors and the marketplace for the Company’s products, and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230102005073/en/
Investor Contact:
Senior Vice President, Investor Relations
kathy.galante@ivericbio.com
or
Media Contact:
Senior Director,
jeannie.neufeld@ivericbio.com
Source:
FAQ
Who is the new board member of IVERIC bio?
What is avacincaptad pegol (ACP) and its significance?
What impact does Dr. Dugel's election have on IVERIC bio?
What are the GATHER clinical trials?